Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Study further the safety and efficacy of the alpha-receptor agonist midodrine
in patients with neurogenic orthostatic hypotension.
II. Assess the quality of life in these patients with this treatment regimen.